Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Decibel Therapeutics (Nasdaq: DBTX) announced that its CEO, Laurence Reid, will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The chat will be available for on-demand viewing starting January 10, 2022, at 7:00 am ET. Interested viewers can access the webcast through Decibel's Investors section on their website, with an archived replay available for 90 days post-event.

Decibel Therapeutics focuses on innovative treatments for hearing and balance disorders, utilizing advanced gene therapies and a proprietary platform.

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The fireside chat will be available for on-demand viewing starting Monday, January 10, 2022 at 7:00 am ET.

A webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com
617-834-0936

FAQ

When will the fireside chat featuring Decibel Therapeutics CEO take place?

The fireside chat is scheduled for January 10, 2022, at 7:00 am ET.

How can I watch the Decibel Therapeutics fireside chat?

You can watch the fireside chat by visiting the Investors section of the Decibel Therapeutics website.

What is Decibel Therapeutics focused on?

Decibel Therapeutics is dedicated to developing treatments for hearing and balance disorders.

How long will the webcast replay of the fireside chat be available?

The archived replay of the webcast will be available for approximately 90 days after the event.

What is the stock symbol for Decibel Therapeutics?

The stock symbol for Decibel Therapeutics is DBTX.